Identifying Potential Effects of Liraglutide on Degenerative Changes

NCT01469351 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can affect brain changes in people with Alzheimer’s disease, as measured by a PIB PET scan.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 34 people

Who can join Ages 50–80 · all sexes

Timeline Started 2012-01 · est. completion 2013-04

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01469351 ↗

Description as written by the study sponsor.

Today Alzheimers disease can not be cured. Animal experiments have shown that the hormone GLP-1 can improve memory in Alzheimer-prone mice. The investigators hypothesis is that a 6-month treatment with the GLP-1 receptor stimulating drug liraglutide will reduce the intracerebral amyloid deposition in the central nervous system (CNS) in patients with Alzheimer's disease (AD) and thereby reduce the clinical symptoms of the disease.

Treatments tested

Liraglutide Drug

Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes. Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation. Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen. 1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used.
non-active study drug Drug

placebo

Main thing measured	PIB PET scan
Sponsor	University of Aarhus
Conditions studied	Alzheimers Disease
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01469351 ↗